Microsurgery Outcomes

Flap salvage, tissue replantation, and cost-effectiveness evidence for the FDA 510(k)-cleared indication

Last Updated: May 26, 2026Reviewed by: Andrei Dokukin, MDTier A — FDA-cleared use contextGRADE: High

FDA-cleared microsurgery indicationOutcome systematic reviews

FDA-Cleared Indication

Venous congestion relief in microsurgical flap salvage and tissue replantation is FDA 510(k)-cleared (K040187, 2004; K132958, 2014; K140907, 2015). This is the only FDA-cleared indication for medicinal leeches in the United States. Medicinal leeches are classified as non-exempt FDA 510(k)-cleared medical devices.

GRADE Evidence Level: Moderate

RCTs with limitations or strong observational studies

Microsurgical flap salvage and tissue replantation represent the most extensively documented clinical application of medicinal leech therapy and the basis for the organism's 2004 FDA clearance. This page presents the complete outcome data for this indication: 3 systematic reviews (Whitaker 2012, Herlin 2017, Rajaram 2024) plus a narrative review including a pooled analysis of 277 reported cases, body-region-specific evidence for digit, ear, and breast replantation, institutional protocols from leading U.S. academic medical centers, cost-effectiveness analysis, and thorough Aeromonas infection management data. A systematic review of 277 reported cases (Whitaker 2012) found a 78% overall salvage rate (216/277), and Herlin 2017 reported 65-85% across studies, with outcomes critically dependent on timing of intervention, prophylactic antibiotic adherence, and institutional protocol standardization.

FDA 510(k) Clearance Status

510(k) Clearances for Medicinal Leeches

510(k) Number	Year	Applicant	Annual U.S. Supply (est.)
K040187	2004	Ricarimpex SAS (France; 150+ years breeding history)	see FDA AccessData
K132958	2014	Biopharm (UK) Ltd. (U.S. distributor: Carolina Biological Supply Co.)	see FDA AccessData

Cleared indications: K040187: an adjunct to the healing of graft tissue when problems of venous congestion may delay healing, or to overcome the problem of venous congestion by creating prolonged localized bleeding. K140907 extends this to skin flaps, skin grafts, surgical reattachments, or other tissues adversely affected by impaired venous blood flow. The medicinal leech (Hirudo verbana) was the second living organism cleared as a medical device by the FDA, following medical maggots for wound debridement.

2024 Regulatory Transfer

On December 30, 2024, the FDA transferred regulatory responsibility for medicinal leeches (product code NRN) from the Center for Devices and Radiological Health (CDRH) to the Center for Biologics Evaluation and Research (CBER), as living organisms more closely align with CBER-regulated products. This administrative transfer does not affect the clinical use or availability of medicinal leeches.

Outcome Metrics at a Glance

78%

Overall Salvage Rate

Reported across 277 cases (Whitaker et al., 2012)

92%

Prophylactic Salvage

vs 67% reactive (p = 0.062, not significant) in fingertip replantation

20%

Infection Rate

7 of 35 patients in one unit (Whitaker 2011); more frequent without prophylaxis

49.75%

Transfusion Rate

Serial hematocrit monitoring required every 4 hours

Systematic Reviews: Converging Evidence

The evidence for leech-mediated flap salvage derives predominantly from systematic reviews of case series — a design limitation imposed by the clinical impossibility of randomizing patients with failing flaps to leech therapy versus no intervention. Withholding an FDA-cleared intervention from a patient with an acutely failing flap would be ethically untenable. Despite this constraint, the convergence of three systematic reviews on salvage rates of 65-85% provides solid evidence for clinical practice.

Systematic Reviews of Medicinal Leech Therapy in Microsurgical Salvage
Study	Design	Population (n=)	Intervention	Key Outcome	Result
Whitaker et al. 2012	Systematic review	Plastic and reconstructive surgery patients with venous congestion across 67 publications (1966-2009) (n=277)	Medicinal leech therapy for flap salvage and tissue replantation	Overall tissue salvage rate, complication profile	78% salvage (216/277); 88.3% without infection vs 37.4% with infection Landmark review. 49.75% transfusion rate; 21.8% overall complication rate (infection rate 14.4%, as cited in later reviews). Male:female ratio ~2:1; age range 2-81 years
Herlin et al. 2017	Systematic review + retrospective case series	Pedicled and free flaps with venous congestion (n=41 studies + 43 patients)	Medicinal leeches with ciprofloxacin + TMP-SMX prophylaxis; 41 studies reviewed + own 43-patient series	Flap salvage success; application protocol	Success 65–85% across reviewed studies (83.7% in the authors' 43-patient series) Recommended ciprofloxacin + TMP-SMX as first-line prophylaxis. Optimal frequency: every 2–8 hours; average duration: 4–10 days
Hackenberger & Janis 2019	Narrative review	Plastic and reconstructive surgery patients (n=NR)	Medicinal leech therapy for venous congestion	Indications, application, number and duration of therapy, risks	Summarizes recent literature for plastic surgery: leeches as an FDA-cleared, nonsurgical option for venous congestion; infection and bleeding are the main risks Plast Reconstr Surg Glob Open 2019;7(12):e2555 (PMID 32537302)
Rajaram et al. 2024	Systematic review	Breast reconstruction patients (75% reconstructive, 25% other breast surgery); 18 studies (4 case series, 14 case reports) (n=4)	Medicinal leech therapy for flap congestion; median 2 leeches/session, 3 sessions/day, 3 days duration	Tissue salvage rate and complication burden	75% salvage; 81% complication rate (infection and anemia) First systematic review dedicated to breast surgery. Concluded leech therapy must be judiciously used given high complication burden

Key Points

Two systematic reviews anchor the salvage figures. Whitaker et al. (2012) reported 77.98% success across 277 cases from 67 publications (1966–2009). Herlin et al. (2017) reported 65–85% success across flap-salvage studies (83.7% in their own 43-patient series) and recommended application every 2–8 hours. Hackenberger and Janis (2019) reviewed indications, application, and risks for plastic surgery, describing leeches as a nonsurgical option for venous congestion.

Rajaram et al. (2024) contributed the first body-region-specific systematic review for breast surgery (18 studies, 28 patients), documenting a 75% salvage rate with an 81% complication rate — reflecting the greater complexity of large-volume flap management compared to digits and ears.

Herlin et al. drew an important mechanistic distinction: leech therapy is effective for intrinsic venous insufficiency within the flap (microthrombi, inadequate venous outflow) but is unlikely to salvage a flap with proximal venous anastomosis or pedicle obstruction , which requires surgical revision.

Evidence Level Classification

No randomized controlled trials exist for microsurgical flap salvage indications, nor are they likely to be conducted. The evidence level is classified as Level IV (systematic review of case series). Despite this classification, the reported salvage rates (77.98% in Whitaker 2012; 65-85% in Herlin 2017), the clear pathophysiologic rationale, the lack of better-evidenced alternatives, and the FDA 510(k) clearance collectively support leech therapy as an accepted nonsurgical option for this indication.

Timing and Application Strategy

Time Is Tissue

Timing matters. In 2,138 breast free flaps, salvage of compromised flaps was 83.7% within the first 24 hours versus 38.6% at days 1–3 (Chang et al. 2016) — surgical salvage, not leech therapy. For leech therapy, Herlin et al. (2017) recommend application every 2–8 hours. In fingertip replantation, prophylactic leeching from the early postoperative period gave complete survival in 12/13 digits versus 8/12 with reactive leeching (92% vs 67%), with fewer complications and re-operations (1/13 vs 6/12, p = 0.030; Kameda et al. 2025).

Pathophysiology of Venous Congestion

Venous obstruction or insufficiency from thrombosis, kinking, vasospasm, or inadequate anastomosis
Blood accumulates in tissue; interstitial pressure rises
Capillary perfusion ceases as arterial inflow is impeded by elevated venous back-pressure
Tissue ischemia and edema develop; flap becomes indurated and cyanotic
Microthrombi cascade in small vessels
Irreversible microvascular damage develops within 6-8 hours without intervention

1. Active Blood Extraction

Each leech ingests 5-15 mL during a 30-90 minute feeding, creating immediate mechanical decompression. The negative pressure from rhythmic pharyngeal muscle contractions actively draws venous blood from the congested tissue bed.

Flap Salvage — Key Individual Studies
Study	Design	Population (n=)	Intervention	Key Outcome	Result
Soucacos et al. 1994	Case series	Replanted fingers/hands (11 patients) and free tissue transfers (18 patients); 29 patients in total (n=29)	Medicinal leech therapy for venous insufficiency in replantation and tissue transfer	Resolution of venous insufficiency	24/29 patients overall had venous insufficiency successfully treated (replantation 9/11, 82%; free tissue transfer 15/18, 83%) One of the largest single-center series for digit/hand replantation
Hayden et al. 1988	Animal experimental (porcine model)	Sacral skin flaps with induced venous occlusion in pigs (n=NR)	Medicinal leech application with laser Doppler blood flow monitoring	Blood flow restoration in congested flaps	Significant increases in blood flow, shown clinically and by laser Doppler perfusion monitoring, after leech application to nine congested pig rump flaps Preclinical confirmation of the microcirculation improvement mechanism. Established the experimental foundation for clinical use
Uncontrolled report (unverifiable) 1998	Controlled study	Pharynx/esophagus defects (98 patients) and auricular injuries (12 patients) (n=98)	Pre- and postoperative hirudotherapy with interstitial polarography monitoring	Tissue oxygen restoration and transplant viability	Oxygen restored in 69.9%; relative normal in 30.2%. Functional outcomes improved 26.2-48.4% vs controls Series of 110 patients (98 pharyngeal/esophageal defects, 12 auricular injuries). Marginal flap necrosis in 12-30% of patients. Transplant viability preserved in all cases
Nguyen et al. 2012	Case series	Native skin (5), local flaps (6), regional flaps (14), free flaps (14) (n=NR)	Medicinal leech therapy with prophylactic antibiotics for venous congestion	Salvage rate by flap type; Aeromonas infection rate with prophylaxis	No total losses (native skin/local flaps); 33.3% salvaged, 33.3% partially salvaged, 33.3% lost (27 regional/free flaps). No Aeromonas hydrophila wound infections Salvaged group required significantly fewer leeches (38 vs 158). Prophylactic antibiotics eliminated Aeromonas infections entirely

Impact of Infection on Salvage

Whitaker et al. (2012) demonstrated that Aeromonas infection catastrophically reduces salvage outcomes: 88.3% salvage without infection vs 37.4% with infection — a 51-percentage-point decline. This single finding supports the antibiotic prophylaxis protocols now recommended in most protocols, although no prospective randomized trials exist. Infection prevention is therefore a priority in treatment.

Leech Consumption as Prognostic Indicator

Nguyen et al. (2012) found that the salvaged group required fewer leeches on average (38 +/- 34 mean) than the lost group (158 +/- 224 mean), suggesting that early favorable response is a prognostic indicator. High leech consumption without clinical improvement within 48 hours should prompt reassessment of the diagnosis, including evaluation for proximal venous obstruction requiring surgical revision.

Response Criteria

Favorable response (flap pinking, reduced turgor, improved capillary refill): continue at current frequency; consider extending interval. Partial response (intermittent improvement with recurrent congestion): continue; assess for proximal venous obstruction. No improvement at the 48-hour reassessment: reassess diagnosis; consider arterial insufficiency, pedicle obstruction, or flap non-viability; surgical revision or flap abandonment may be necessary. Success criteria for discontinuation: stable flap color, normal capillary refill, no recurrence of congestion as leech application is tapered or stopped.

Digit Replantation Evidence

FDA-Cleared Indication

Digital replantation with venous congestion falls within the FDA 510(k)-cleared indication for venous decompression. Prophylactic leeching achieved 92% complete digit survival (12/13) versus 67% (8/12) with reactive application in a small retrospective fingertip-replantation series (p = 0.062, not significant); early complications and re-operations were significantly fewer with prophylaxis (p = 0.030).

Distal fingertip amputation at or distal to the distal interphalangeal joint presents a unique microsurgical problem. At this level, veins are typically too small (commissural veins at the nail base measure about 0.3–0.5 mm) for reliable anastomosis. Even when venous repair is attempted, thrombosis rates are high. The result is a replanted digit with arterial inflow but inadequate venous outflow — the precise indication for which the FDA cleared medicinal leeches in 2004. In one series of 50 distal finger amputations (venous problems in 16), the authors estimated that leech use improved the survival rate of distal digital replantation by 26% (Baudet, Blood Coagul Fibrinolysis, 1991; PMID 1772991).

Digital Replantation — Key Studies
Study	Design	Population (n=)	Intervention	Key Outcome	Result
Prophylactic vs. reactive study 2020	Retrospective cohort	Distal digit replantation patients (n=NR)	Prophylactic leeching (before congestion develops) vs reactive leeching (after congestion is clinically apparent)	Complete digit survival and early complication rate	92% survival (prophylactic) vs 67% survival (reactive); p = 0.062 (not statistically significant) Early complications 8% (prophylactic) vs 50% (reactive). The 25-percentage-point survival difference was not statistically significant (p = 0.062); early complications and re-operations were significantly fewer with prophylactic leeching (p = 0.030)
Soucacos et al. 1994	Case series	29 patients with venous insufficiency after replantation of digits/hands (n = 11) or free tissue transfer (n = 18) (n=29)	Medicinal leech therapy for venous congestion in digit/hand replantation	Digit/hand salvage rate	Venous insufficiency successfully treated in 24/29 patients (83%): 9/11 replantations and 15/18 free tissue transfers One of the largest single-center digit replantation series with leech therapy
Lee et al. 2019	Retrospective cohort	Digit revascularization and replantation patients (n=201 digits (48 leeched))	Medicinal leech therapy with variable duration; identified 4.5-day threshold	Digit survival by leeching duration	Digits leeched >4.5 days had significantly higher survival rates Longer leeching associated with higher transfusion incidence and longer hospital stay. Important for cost-efficiency calculations
Brody, Maloney & Hentz 1989	Case series	Digit replantation patients with relative contraindications for procedure (n=NR)	Medicinal leech therapy when venous repair was technically impossible	Digit salvage; infection and transfusion rates	All digits salvaged; no infections; no transfusions required Unusually favorable complication profile. Demonstrated feasibility in high-risk patients with relative contraindications
Barnett 1998	Case series	Complete fingertip amputations distal to the DIP joint (n=NR)	Artery-only replantation with medicinal leech therapy for venous decompression	Fingertip salvage in amputations where venous repair was impossible	Successful replantation in majority of cases; leech therapy sustained venous drainage until neovascularization Demonstrated viability of artery-only replantation approach for distal amputations

Prophylactic vs Reactive Leeching

A retrospective study of 25 digits (12 reactive, 13 prophylactic) demonstrated a 25-percentage-point improvement in survival (67% to 92%; p = 0.062, not statistically significant) and a significant reduction in early complications (50% to 8%; p = 0.030) with prophylactic leeching. The implication: in distal digit replantation where venous anastomosis is absent or unreliable, prophylactic leech application (2-3 times daily from the early postoperative period) may be adopted as a standard approach rather than waiting for congestion to develop.

Hematologic Monitoring Protocol

Parameter	Frequency	Action Threshold
Hemoglobin/Hematocrit	Every 4 hours during active leeching	Transfuse pRBC if Hgb <7 g/dL (<8 g/dL with cardiac comorbidity)
Platelet count	Every 8 hours	Platelet transfusion if <50,000/µL with active bleeding
Coagulation panel (PT/INR, aPTT)	Daily	Correct coagulopathy if bleeding is excessive
Type and crossmatch	On admission	Maintain 2 units pRBC available at all times
Fluid balance	Continuous	Aggressive IV hydration to compensate for blood loss

Ear Replantation Evidence

FDA-Cleared Indication

Ear replantation with venous congestion falls within the FDA 510(k)-cleared indication. Artery-only replantation with leech-assisted venous decompression is a recognized but less successful option: in a 2026 systematic review (Zuhurlu et al., PMID 42720919), 17 of 25 artery-only ear replants (68.0%) survived versus 58 of 64 (90.6%) with arterial and venous repair.

Total ear amputation is a devastating injury. The auricle's complex three-dimensional architecture — thin cartilaginous framework covered by delicate skin — makes reconstruction with prosthetics or autologous tissue grafts aesthetically inferior to replantation. Yet microsurgical ear replantation remains among the most technically demanding procedures in plastic surgery: vessels are small (0.3-0.7 mm), vessel identification is difficult, and the distinction between arteries and veins can be impossible in the traumatized field. At least 84 ear replantations have been described in the published literature since Pennington's first successful microsurgical ear replantation in Sydney in 1980.

The accumulated evidence supports a significant finding: artery-only replantation with medicinal leech therapy for venous decompression is a viable clinical approach when venous repair is technically impossible. Surgeons should not abandon ear replantation attempts solely because venous outflow cannot be established microsurgically.

Ear Replantation — Key Studies
Study	Design	Population (n=)	Intervention	Key Outcome	Result
Cho (aggregate analysis) 2016	Literature analysis	Total ear replantation cases from published literature (n=NR)	Microsurgical replantation with leech-assisted venous decompression	Overall survival; salvage rate after venous congestion	~68% overall survival; 80% salvage rate after replantation; 57% developed venous congestion requiring external decompression Significant finding: artery-only replantation with leech decompression demonstrated as viable clinical approach
Concannon & Puckett 1999	Case report	Partial ear amputation (n=NR)	Microsurgical partial ear replantation with medicinal leech therapy for venous decompression	Ear salvage	Successful replantation with leech-assisted venous drainage Published in Annals of Plastic Surgery
Cho & Bhangoo 1998	Case report	Pediatric patient (child) with complete ear amputation (n=NR)	Microsurgical ear replantation without venous repair; leeches for venous decompression	Ear salvage without venous anastomosis	Successful replantation. Third reported case of ear replantation in a child without venous repair Published in British Journal of Plastic Surgery. Demonstrated pediatric applicability
Kind et al. 2001	Case report	Complete ear amputation (n=NR)	Complete ear replantation without venous anastomosis; leech therapy for venous decompression	Ear salvage with artery-only technique	Successful complete ear replantation relying entirely on leech therapy for venous drainage Published in Microsurgery. Reinforced viability of artery-only approach
Mutimer, Banis & Upton 1987	Case series	Total ear amputation patients; vessel identification difficult in traumatized field (n=NR)	Ear reattachment with leech therapy when heparin and plasminogen activators failed	Ear salvage and microcirculation restoration	Successful salvage in cases where pharmacologic approaches (heparin, plasminogen activators) failed Landmark pediatric case of 5-year-old boy demonstrated leech efficacy in children

Clinical Algorithm for Traumatic Ear Amputation

Attempt microsurgical replantation — arterial and, if possible, venous anastomosis
If venous anastomosis fails or is impossible — proceed with arterial-only replantation
Initiate leech therapy immediately in the early postoperative period for venous decompression
Continue leech therapy for about 3-17 days (mean 8.5 days) until neovascularization establishes collateral venous drainage
Monitor hematologic parameters closely; transfuse as indicated

Expected salvage rate with this approach: about 80% in a 1998 literature review of ear replantations (small case numbers).

Systems-Level Prevention

Rajaram and colleagues conducted the first systematic review dedicated to leech therapy in breast surgery, published in the Journal of Clinical Medicine in 2024. The review encompassed 18 studies (4 case series, 14 case reports) totaling 28 patients. Leeching protocol: median 2 leeches per session, 3 sessions per day, 3 days duration. Tissue salvage rate: 75%. Complication rate: 81%, dominated by infection and anemia. The review concluded that leech therapy in breast surgery must be "judiciously used" given this high complication burden. For DIEP flap congestion, supplementary venous anastomosis may offer superior outcomes.

Decision Algorithm for Breast Reconstruction Flap Congestion

Identify congestion: Dark color, turgor, brisk dark capillary refill, tissue oximetry (rStO2) <30% (a device-specific threshold for vascular compromise)
Immediate surgical exploration: Rule out pedicle kinking, compression, or thrombosis
If surgically correctable: Revise anastomosis or augment venous outflow with supplementary vein
If not surgically correctable: Initiate leech therapy
Monitor response: If no improvement, re-explore surgically
Continue if responding: Up to 5-7 days with close hematologic monitoring
Accept partial salvage: In large-volume flaps, partial necrosis with preservation of sufficient tissue volume may still achieve acceptable reconstruction

Institutional Protocols: U.S. Academic Medical Centers

The implementation of leech therapy in U.S. hospitals has matured from ad hoc bedside application to standardized, protocol-driven care. Three institutional models merit specific discussion as frameworks for implementation.

University of Iowa — Head and Neck Protocol

Leeches applied every 2 hours for acutely congested free flaps
Concomitant systemic anticoagulation per microsurgical flap protocol
Dedicated nursing assessment of flap perfusion between leech applications

Flap Monitoring Protocol

Assessment	Frequency	Action Thresholds
Flap color, turgor, capillary refill	Every 1-2 hours	Dark purple/turgid: apply leeches; pale/cool: evaluate arterial inflow
Tissue oximetry (if available)	Continuous	StO&sub2; fall of 20% or more per hour sustained for over 30 minutes: suspected vascular compromise (thresholds vary by device and series)
Hemoglobin/hematocrit	Every 4-8 hours	Transfuse if Hgb <7 g/dL (or <8 g/dL in cardiac comorbidity)
Temperature at bite site	With each assessment	Rising temperature may indicate infection
Wound culture	If signs of infection	Start empiric treatment; adjust based on culture sensitivities

Cost-Effectiveness Analysis

Published cost analyses provide a framework for evidence-based resource allocation in leech therapy. Individual leeches cost approximately $10-30 each in the USA. The number used per course varies widely.

Cost-Effectiveness Data
Study	Design	Population (n=)	Intervention	Key Outcome	Result
Cost-efficiency study 2022	Cost-effectiveness analysis	Revascularized and replanted digits with venous congestion (n=NR)	Medicinal leech therapy; incremental cost per additional day: $2,951	Cost-efficiency thresholds using $100,000/QALY benchmark	Cost-efficient through 3 days (single digit), 5 days (thumb), 7 days (multiple digits) Hospitalization cost range: $12,622-$123,563. Published in Plastic and Reconstructive Surgery — Global Open
King et al. 2022	Retrospective cohort with cost analysis (conference abstract)	Digit revascularization and replantation patients (n=NR)	Leech therapy duration analysis with associated resource use	Survival rate by therapy duration; transfusion and hospitalization costs	Success rate: 69% (1-3 days), 42% (4-7 days), 8% (>7 days) Success rate fell with longer leeching; each additional day of leech therapy cost about $2,951 on average, and cost efficiency diminished with longer therapy duration
Nguyen et al. 2012	Case series with resource analysis	39 patients with venous congestion across flap types (n=39)	Leech therapy with quantification of leech consumption by outcome group	Leech use as prognostic indicator	Salvaged group: 38.3 leeches (mean); lost group: 157.9 leeches (mean). 57.9% transfusion rate Lower leech consumption correlates with favorable prognosis, suggesting early response predicts outcome

Cost-Efficiency Thresholds

Using the standard $100,000/QALY benchmark at $2,951 per additional day of leech therapy:

Indication	Cost-Efficient Through
Single digit	3 days
Thumb	5 days
Multiple digits	7 days

Clinical Interpretation

These cost-efficiency thresholds should inform — but not dictate — clinical decision-making. After the cost-efficiency threshold is reached, the diminishing probability of salvage combined with accumulating hospitalization, transfusion, and complication costs makes continued leeching economically difficult to justify. However, the decision remains clinical, and factors including functional significance of the tissue (thumb vs. fifth digit), patient preferences, and individual response trajectory should guide shared decision-making with patients and families.

Aeromonas Infection Management

The Primary Complication: Aeromonas hydrophila

Aeromonas hydrophila (and the closely related A. veronii) are obligate gut symbionts of medicinal leeches, present in 62-100% of leech gut aspirate cultures. A. hydrophila accounts for 88% of all leech therapy infectious complications. Whitaker reported flap salvage rates of approximately 78% across 277 cases (PMID 22407551) — and antibiotic prophylaxis against Aeromonas is highly advisable (Herlin 2017, PMID 27427444).

Infection Rates by Prophylaxis Status

Prophylaxis Status	Infection Rate	Source
No prophylaxis	7-20%	Aggregate literature
With appropriate prophylaxis	<5%	Aggregate literature
One series of 39 patients (Nguyen et al.)	0% (0/39)	Nguyen et al. 2012
Without optimized prophylaxis (Palm et al.)	Infections occurred in this group only	Palm et al. 2022

Aeromonas Infection — Key Studies and Resistance Reports
Study	Design	Population (n=)	Intervention	Key Outcome	Result
Lineaweaver et al. 1992	Multicenter case series	Replantation and flap surgery patients with Aeromonas infection (n=NR)	Documentation of A. hydrophila infections following leech therapy	Infection characteristics, timing, and severity	Onset 24 hours to >10 days post-application; severity from minor wound complications to tissue loss and sepsis Seminal study that established the mandate for routine antibiotic prophylaxis during leech therapy
Palm et al. 2022	Quality improvement study	Patients receiving leech therapy at a tertiary academic medical center (n=NR)	Standardized EMR order panel linking leech orders to automatic antibiotic prophylaxis	Infection rate with vs without optimized prophylaxis protocol	Infections occurred exclusively in subset without optimized prophylaxis; zero infections with EMR-linked protocol Systems-level intervention. Panel includes leech order + antibiotics + labs + nursing protocol + pharmacy notification
Nguyen et al. 2012	Retrospective case series	39 patients treated with leeches for venous congestion in native skin, local, regional and free flaps (n=39)	Leech therapy; no prophylaxis protocol was designed or compared	Aeromonas hydrophila infection rate	No Aeromonas wound infection observed (0/39) Incidental observation in a flap-outcome study; not evidence that a prophylaxis protocol eliminates infection
Giltner et al. 2013	Case report	Patient with cellulitis despite ciprofloxacin prophylaxis (n=NR)	Ciprofloxacin monoprophylaxis during leech therapy	Breakthrough Aeromonas infection	Ciprofloxacin-resistant A. hydrophila cellulitis developed despite prophylaxis Published in Journal of Clinical Microbiology. Early warning of emerging ciprofloxacin resistance
Wilmer et al. 2014	Case report	Digit replantation patients with resistant Aeromonas infection (n=NR)	Leech therapy for digit replantation with ciprofloxacin prophylaxis	Ciprofloxacin-resistant infection in digit replantation	2 cases of ciprofloxacin-resistant A. hydrophila infection complicating digit replantation Published in Journal of Hand Surgery. Reinforced need for dual-agent prophylaxis

Antibiotic Prophylaxis Protocol

Recommended Dual-Agent Prophylaxis

Agent	Dose	Notes
Ciprofloxacin (first-line)	500 mg PO BID	Historically the standard; rising resistance noted
Trimethoprim-sulfamethoxazole (TMP-SMX)	160/800 mg PO BID	Combination agent; addresses resistance gap
Alternative: ceftriaxone	1 g IV daily	Third-generation cephalosporin; used at some centers

Critical timing: Prophylaxis must begin before the first leech is applied. Continue throughout the entire leech therapy course plus 24-48 hours after the last application. First-generation cephalosporins are inadequate due to intrinsic Aeromonas resistance.

The Ciprofloxacin Resistance Crisis

Standard ciprofloxacin monoprophylaxis is increasingly unreliable. Published case reports document ciprofloxacin-resistant A. hydrophila infections following leech therapy (Giltner 2013, Patel 2013, Wilmer 2013). In one hospital's leech-tank surveillance, 6 of 21 Aeromonas isolates were not ciprofloxacin-susceptible (Wilmer et al. 2013), and in a freshwater survey plasmid-mediated fluoroquinolone resistance (PMQR) genes were found in 42% of Aeromonas isolates that still tested susceptible (Frontiers in Cellular and Infection Microbiology 2022). In a multicenter retrospective cohort, 7 of 59 leech-treated patients (11.9%) developed a surgical site infection despite antimicrobial prophylaxis (ciprofloxacin in 61% of those given prophylaxis), and all four Aeromonas isolates were resistant to the chosen agent (Kruer et al., 2015). Dual-agent prophylaxis (ciprofloxacin + TMP-SMX) is recommended as first-line (Herlin et al. 2017).

Proactive Batch Surveillance Protocol

An innovative approach to resistance management developed following a multidrug-resistant case (Masters et al., J Glob Antimicrob Resist 2020):

On delivery: Sacrifice one leech per batch of 50 for culture and sensitivity testing
Every 30 days: Repeat culture of one leech from each stored batch
Prophylaxis: Directed toward the susceptibility profile of the batch in use
Quarantine: Batches harboring multidrug-resistant isolates are quarantined and not used for patient care

Result: No further leech-associated infections after protocol implementation.

Immunocompromised Patients

Severe and even fatal infections following leech therapy in immunocompromised patients have been documented. While no deaths have been directly attributed to leech therapy in modern published literature, near-fatal sepsis has occurred. Leech therapy in immunocompromised patients requires heightened vigilance, aggressive prophylaxis, and explicit informed consent regarding elevated infection risk.

Comparison with Alternative Venous Decompression Methods

Leeches are not the only option for venous decompression, though they remain the standard of care. A 2011 systematic review of chemical and mechanical alternatives found Grade B evidence that device prototypes show proof of concept for reproducing leech action (suction plus chemical anticoagulation), but heterogeneity of the studies precluded meta-analysis.

Venous Decompression Methods: Comparative Overview

Method	Advantages	Limitations
Medicinal leeches (standard of care)	Combined mechanical + pharmacologic effect; 78% salvage; FDA 510(k)-cleared	Infection risk (Aeromonas); transfusion requirements; patient aversion
Heparin pledgets / chemical leech	Available; easy application; local action	Less effective for free flaps; no pharmacologic synergy
Subcutaneous heparin + scarification	No infection risk	Requires repeated scarification; less blood removal
Negative pressure wound therapy (NPWT)	No infection risk; continuous drainage	No anticoagulant effect; limited data
Hyperbaric oxygen therapy	May reduce ischemia-reperfusion injury	Expensive; logistically difficult; adjunctive only

Evidence Summary and GRADE Assessment

Level of Evidence by Microsurgical Indication

Indication	Best Available Evidence	Level	FDA Status
Venous congestion in flaps/replants	Systematic reviews (Whitaker 2012, Herlin 2017); narrative review (Hackenberger & Janis 2019)	IV (SR)	FDA 510(k)-cleared
Digit replantation	Case series, retrospective studies	IV	FDA 510(k)-cleared
Ear replantation	Case reports/series (>84 cases cumulative)	IV	FDA 510(k)-cleared
Breast reconstruction flap salvage	Systematic review (Rajaram 2024)	IV (SR)	FDA 510(k)-cleared
Head and neck free flap reconstruction	Uncontrolled Russian-language report, not independently verifiable	III	FDA 510(k)-cleared

Why No Randomized Controlled Trials Exist

The absence of RCTs for microsurgical flap salvage is not an evidence gap — it reflects the ethical impossibility of withholding an FDA-cleared intervention from patients with acutely failing tissue transfers. The reported salvage rates (77.98% in Whitaker 2012; 65-85% in Herlin 2017), the clear pathophysiologic rationale, and the lack of better-evidenced alternatives collectively establish the evidence base for this indication.

Evidence Gaps and Research Priorities

Multicenter Prospective Registries

Standardized data collection across microsurgical centers with defined endpoints (salvage rate, time to intervention, hematologic parameters, infection rate, resistance profiles) would strengthen the evidence base beyond retrospective case series.

Related Research

Clinical Literature2016

Leech Therapy For The Treatment Of Venous Congestion In Flaps, Digital Re-Plants And Revascularizations - A Two-Year Review From A Regional Centre

Of 20 venously congested tissues in 18 patients treated over two years, leech therapy salvaged 13 (65%); salvage was complete for pedicled flaps (6/6) but poor for digital replants (1/4) and free flaps (0/2).

Butt AM et al. · Journal of Ayub Medical College, Abbottabad

Clinical Literature1994

The use of medicinal leeches, Hirudo medicinalis, to restore venous circulation in trauma and reconstructive microsurgery

In 24 of 29 patients, venous insufficiency after digit/hand replantation or free tissue transfer was successfully treated with Hirudo medicinalis, supporting leech therapy as a valuable alternative method for restoring venous drainage in replantation and free flap patients.

Soucacos PN, Beris AE, Malizos KN et al. · International angiology

Clinical Literature2020

A global view of digital replantation and revascularization

A global review notes that digital replantation survival rates vary by region, with Asian surgeons managing challenging cases; multi-digit replantation can follow structure-by-structure or digit-by-digit methods needing 3 to 4 teams for all 10 digits, while flow-through or pedicled flaps repair soft-tissue and vascular defects.

Tang JB et al. · Clinics in plastic surgery

Clinical Literature2020

Pedicled Anterolateral Thigh and Radial Forearm Free Flap Phalloplasty for Penile Reconstruction in Patients With Bladder Exstrophy

A 6-year review of 11 exstrophy-epispadias patients undergoing phalloplasty found flap survival in all cases with radial forearm free flap or pedicled anterolateral thigh flap, though the latter frequently required debulking and one patient died from pulmonary embolism.

Harris TGW et al. · The Journal of urology

Clinical Literature2018

The Use of Medicinal Leeches for the Treatment of Venous Congestion in Replanted or Revascularized Digits

Of 25 digits with venous congestion after replantation or revascularization at middle or proximal phalangeal level, medicinal leech treatment salvaged 11 (44.4%); the authors suggest it may be less effective when treatment is late or tissue volume is high.

Arami A et al. · The Journal of hand surgery

Clinical Literature2018

Experience with pharmacologic leeching with bivalirudin for adjunct treatment of venous congestion of head and neck reconstructive flaps

In a single-institution retrospective review, 10 patients received local bivalirudin injection for venous congestion of head-and-neck free flaps; of the 8 flaps whose outcome could be assessed, 4 developed partial necrosis and 1 developed complete necrosis, and bivalirudin was judged a safe, feasible adjunct therapy.

Harun A et al. · Microsurgery